Cognitive and Functional Influences of Vildagliptin, a DPP-4 Inhibitor, Added to Ongoing Metformin Therapy in Elderly with Type 2 Diabetes

Taşçı, İlker; Naharcı, Mehmet İlkin; Bozoğlu, Ergün; Safer, Umut; Aydoğdu, Aydoğan; Yilmaz, Başak; Yılmaz, Gülay Can; Doruk, Hüseyin

doi:10.2174/18715303113139990037

Cited by 23 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a pilot study (n=11), addition of vildagliptin to metformin produced no change in cognitive performance after an average of 11 months. However, this study was severely limited by its brief cognitive assessment and small sample size [9].…”

Section: Dpp-iv Inhibitorsmentioning

confidence: 99%

Effects of incretin-based therapies on neurocognitive function in humans: A systematic review of the literature

Dumbrill

Moulton

2018

Primary Care Diabetes

View full text Add to dashboard Cite

show abstract

Section: Dpp-iv Inhibitorsmentioning

confidence: 99%

Effects of incretin-based therapies on neurocognitive function in humans: A systematic review of the literature

Dumbrill

Moulton

2018

Primary Care Diabetes

View full text Add to dashboard Cite

show abstract

“…• To keep the patient asymptomatic and free of acute metabolic complications • To prevent development and/or progression of diabetic complications • To preserve cognitive function and physical activity • To ensure adequate quality of life • To avoid adverse drug reactions metformin therapy was associated with stable cognitive and functional performance over 1-year follow-up [89].…”

Section: Potential Benefits Of Dpp-4 Inhibitor-based Treatments In Elmentioning

confidence: 99%

Dipeptidyl peptidase‐4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes

Avogaro

Dardano

Kreutzenberg

et al. 2014

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

The prevalence of type 2 diabetes mellitus (T2DM) among elderly people is increasing. Often associated with disabilities/comorbidities, T2DM lowers the chances of successful aging and is independently associated with frailty and an increased risk of hypoglycaemia, which can be further exacerbated by antihyperglycaemic treatment. From this perspective, the clinical management of T2DM in the elderly is challenging and requires individualization of optimum glycaemic targets depending on comorbidities, cognitive functioning and ability to recognize and self-manage the disease. The lack of solid evidence-based medicine supporting treatment guidelines for older people with diabetes further complicates the matter. Several classes of medicine for the treatment of T2DM are currently available and different drug combinations are often required to achieve individualized glycaemic goals. Many of these drugs, however, carry disadvantages such as the propensity to cause weight gain or hypoglycaemia. Dipeptidyl peptidase-4 (DPP-4) inhibitors, a recent addition to the pharmacological armamentarium, have become widely accepted in clinical practice because of their efficacy, low risk of hypoglycaemia, neutral effect on body weight, and apparently greater safety in patients with kidney failure. Although more information is needed to reach definitive conclusions, growing evidence suggests that DPP-4 inhibitors may become a valuable component in the pharmacological management of elderly people with T2DM. The present review aims to delineate the potential advantages of this pharmacological approach in the treatment of elderly people with T2DM. Keywords: comorbidities, diabetes treatment, frailty, hypoglycaemia, incretin therapy, renal impairment Date submitted 20 December 2013; date of first decision 3 February 2014; date of final acceptance 20 May 2014 IntroductionIt is well known and has been amply shown that the global population with diabetes has been growing over the past decades and that it will continue to increase even further in the near future [1]. What is less appreciated is that diabetes, particularly in the Western Hemisphere, will become a major problem in the elderly population. Life expectancy has increased in the general population as well as in those with diabetes [1]. More people with diabetes will grow older and more people will develop diabetes later in life. The result will be an increase in the prevalence of diabetes in the elderly. The number of people with diabetes aged ≥65 years is expected to double between 2010 and 2015, with the actual number rising from 55 to almost 130 million [2].Diabetes in the elderly is often associated with disabilities, and >70% of the elderly people with type 2 diabetes mellitus (T2DM) have some degree of impaired physical activity [3]. Elderly subjects, especially those with diabetes, tend to be frailer and experience weight loss, to be more prone to exhaustion, to have lower energy expenditure, slower gait speed and Correspondence to: Angelo Avogaro, MD, PhD, Department of Medi...

show abstract

“…Имеются данные экспериментальных и клинических исследований, что некоторые ингибиторы ДПП-4, особенно ситаглиптин, имеют положительное влияние на когнитивные функции [94][95][96][97][98][99][100][101].…”

Section: ингибиторы дипептидилпептидазы 4 типаunclassified

Cognitive impairment in patients with type 2 diabetes mellitus: prevalence, pathogenetic mechanisms, the effect of antidiabetic drugs

et al. 2018

View full text Add to dashboard Cite

In recent years, a large amount of data has been accumulated on the relationship between cognitive impairment, dementia and diabetes mellitus. This article presents an overview of modern literature, including the definition of cognitive functions, the modern classification of cognitive impairment, pathogenetic mechanisms of diabetes mellitus influence on the development of cognitive impairment and dementia (neurogenesis, integrity of the blood-brain barrier, systemic inflammatory reactions, hyper- and hypoglycemia, insulin resistance, vascular dysfunction of the microvasculature and increase in glucocorticosteroids). The influence of anti-diabetic medications on cognitive functions has been examined in detail: insulin preparations, oral hypoglycemic agents of the biguanide group (metformin), thiazolidinediones (rosiglitazone and pioglitazone), sulfonylurea derivatives (glycazide, glipizide), a-glucosidase (acarbose) inhibitors, incretin-directed therapy (receptor agonists glucan-like peptide (exenatide and liraglutide) and inhibitors of dipeptidylpeptidase type 4 (sitagliptin, vildagliptin and alogliptin)), sodium glucose inhibitors cotransporter type 2. The data demonstrating a multidirectional effect on the cognitive functions of various antidiabetic drugs is presented, the possible influence on the rate of progression of cognitive impairment and the risk of dementia of intensive control of plasma glucose level in comparison with the standard decrease in patients with type 2 diabetes is analyzed.

show abstract

Cognitive and Functional Influences of Vildagliptin, a DPP-4 Inhibitor, Added to Ongoing Metformin Therapy in Elderly with Type 2 Diabetes

Abstract: In this pilot study, addition of vildagliptin to ongoing metformin therapy in elderly with diabetes was accompanied by stable cognitive and functional performance after almost one year of follow-up.

Cited by 23 publications

References 0 publications

Effects of incretin-based therapies on neurocognitive function in humans: A systematic review of the literature

Effects of incretin-based therapies on neurocognitive function in humans: A systematic review of the literature

Dipeptidyl peptidase‐4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes

Cognitive impairment in patients with type 2 diabetes mellitus: prevalence, pathogenetic mechanisms, the effect of antidiabetic drugs

Contact Info

Product

Resources

About